In patients with T-cell non-Hodgkin lymphoma (NHL) undergoing hematopoietic cell transplantation (HCT), delaying either autologous or allogeneic HCT results in significantly worse outcomes, according to an analysis of 241 transplants reported to CIBMTR (Center for International Blood and Marrow Transplant Research). Patients transplanted after more than two lines of prior therapy had significantly higher risks of overall mortality (hazard ratio [HR], 5.02; 95% CI, 2.15-11.72; p<0.001), relapse (HR, 3.00; 95% CI, 1.56-5.71; p<0.001), and non-relapse mortality (HR, 7.04; 95% CI, 1.68-29.61; p=0.008). The researchers concluded that "... both toxicity and efficacy are optimized by fewer prior chemotherapy regimens, and transplantation is most beneficial when offered as part of first- or second-line therapy."
Earlier HCT Improves Outcomes in T-cell NHL
Aug 2013